Chemoprevention of Breast Cancer: Summary of the Evidence, Table 2. Comparison of Randomized Controlled Trials of Breast Cancer Chemoprevention

You Are Here: AHRQ Home > Clinical Information > U.S. Preventive Services Task Force (USPSTF) > Guide to Clinical Preventive Services, 2001-2004 > Chemoprevention: Breast Cancer > Summary of the Evidence

Table 2. Comparison of Randomized Controlled Trials of Breast Cancer Chemoprevention

Study	Family History (%)	ER+ Tumors² (%)	HRT Use³ (%)	Loss to Followup (%)	Discontinuation of Study Drug (%)		Women Who Took Tamoxifen for > 5 Years (n[%])
Study	Family History (%)	ER+ Tumors² (%)	HRT Use³ (%)	Loss to Followup (%)	Placebo	Treatment	Women Who Took Tamoxifen for > 5 Years (n[%])
Royal Marsden (19)	100	63	26	11	31	40	79 (6.3)
Italian Study (21,23)¹	21	43	14	0.6	25	28	77 (2.9)
Italian Study (21,23)¹	21	Unk⁴	29	NA	34	36	2,462 (45)
Breast Cancer Prevention Trial (20)	76	71	0	1.6	20	24	2,424 (36.9)
Multiple Outcomes of Raloxifene Evaluation (22)	12	60	10	NA	25⁵	22⁵	Not applicable

¹First line refers to initial results published in 1998; second line refers to results with longer follow up published in 2002.
²ER+, estrogen receptor-positive.
³HRT, hormone replacement therapy.
⁴Unk, unknown; NA, data not available.
⁵Cumulative withdrawal at 36 months (includes loss to followup).

Return to Contents
Return to Document